About Helios
Helios is a company based in Tokyo (Japan) founded in 2011. It operates as a HealthTech. Helios has raised $29.17 million across 2 funding rounds from investors including Nikon, European Union and Sumitomo Dainippon Pharma. The company has 65 employees as of December 31, 2024. Helios offers products and services including iPSC Regenerative Medicine, Somatic Stem Cell Regenerative Medicine, and Cancer Immunotherapy (NK Cells). Helios operates in a competitive market with competitors including Kriya Therapeutics, Annexon, Aldeyra, Blue Rock Therapeutics and Nicox, among others.
- Headquarter Tokyo, Japan
- Employees 65 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Healios Kk
-
Annual Revenue
$3.57 M (USD)362.81as on Dec 31, 2024
-
Net Profit
$-27.01 M (USD)-10.78as on Dec 31, 2024
-
EBITDA
$-16.56 M (USD)13.37as on Dec 31, 2024
-
Total Equity Funding
$29.17 M (USD)
in 2 rounds
-
Latest Funding Round
$55.99 K (USD), Grant
Jun 01, 2019
-
Investors
Nikon
& 2 more
-
Employee Count
65
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Helios
Helios is a publicly listed company on the TSE with ticker symbol 4593 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Helios
Helios offers a comprehensive portfolio of products and services, including iPSC Regenerative Medicine, Somatic Stem Cell Regenerative Medicine, and Cancer Immunotherapy (NK Cells). The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Innovative therapies are developed using iPSC technology.
Treatments are created using somatic stem cells.
Cancer treatments are developed using NK cells.
Funding Insights of Helios
Helios has successfully raised a total of $29.17M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $55.99 thousand completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Grant — $55,992
-
First Round
First Round
(08 Oct 2013)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2019 | Amount | Grant - Helios | Valuation |
investors |
|
| Oct, 2013 | Amount | Series A - Helios | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Helios
Helios has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Nikon, European Union and Sumitomo Dainippon Pharma. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location | |
|
Pharmaceuticals, food ingredients, additives, and veterinary products are manufactured.
|
Founded Year | Domain | Location | |
|
Nikon is recognized as a key technology solutions company.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Helios
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Helios
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Helios Comparisons
Competitors of Helios
Helios operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Annexon, Aldeyra, Blue Rock Therapeutics and Nicox, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| domain | founded_year | HQ Location |
Stem cell therapies are developed for cardiovascular and neurological diseases.
|
|
| domain | founded_year | HQ Location |
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
|
| domain | founded_year | HQ Location |
Mobile SDK developed for app engagement and monetization strategies.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Helios
Frequently Asked Questions about Helios
When was Helios founded?
Helios was founded in 2011 and raised its 1st funding round 2 years after it was founded.
Where is Helios located?
Helios is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
Is Helios a funded company?
Helios is a funded company, having raised a total of $29.17M across 2 funding rounds to date. The company's 1st funding round was a Series A of $29.17M, raised on Oct 08, 2013.
How many employees does Helios have?
As of Dec 31, 2024, the latest employee count at Helios is 65.
What is the annual revenue of Helios?
Annual revenue of Helios is $3.57M as on Dec 31, 2024.
What does Helios do?
Helios is focused on the development of regenerative medicine therapies to expand treatment options for patients worldwide. The company operates in sectors such as iPSC regenerative medicine, somatic stem cell therapies, and cancer immunotherapy using NK cells. Solutions are being researched for conditions like age-related macular degeneration, liver diseases, stroke, and acute respiratory distress syndrome (ARDS). Innovative strategies are employed to deliver new treatment methods and hope to patients globally.
Who are the top competitors of Helios?
Helios's top competitors include Annexon, Alimera Sciences and MeiraGTx.
What products or services does Helios offer?
Helios offers iPSC Regenerative Medicine, Somatic Stem Cell Regenerative Medicine, and Cancer Immunotherapy (NK Cells).
Is Helios publicly traded?
Yes, Helios is publicly traded on TSE under the ticker symbol 4593.
Who are Helios's investors?
Helios has 3 investors. Key investors include Nikon, European Union, and Sumitomo Dainippon Pharma.
What is Helios's ticker symbol?
The ticker symbol of Helios is 4593 on TSE.